抗小鼠CD137抗体（克隆号LOB12.3）引用文献
抗小鼠CD137单克隆抗体（克隆号LOB12.3）引用文献如下：
1. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
2. Intratumoral activation of 41BB co-stimulatory signals enhances CD8 T cell expansion and modulates tumor-infiltrating myeloid cells
3. TCR-independent CD137 (4–1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation
4. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
5. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
6. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
7. Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking
8. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
9. 4-1BB stimulation with concomitant inactivation of adenosine A2B receptors enhances CD8+ T cell antitumor response
10. Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity
……
Syd Labs抗小鼠CD137重组抗体（克隆号LOB12.3）：
Syd Labs 重组抗小鼠CD137（TNFRSF9 or 4-1BB）单克隆抗体（克隆号LOB12.3），大鼠IgG1 kappa，体内实验级（In Vivo Grade Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody（Clone LOB12.3）,Rat IgG1 Kappa，货号：PA007275.r1）是用哺乳动物细胞生产的重组抗体，适用于体外和体内研究，包括ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受小鼠4-1BB蛋白影响的生物学途径的测定等。
如果需要了解更多有关Syd Labs 重组抗小鼠CD137抗体(克隆号LOB12.3)信息，比如Syd Labs 抗小鼠CD137重组抗体使用说明等资料，欢迎联系多找找获取。
特此声明：多找找推广的所有产品和服务的价格、货期和规格等信息如有更改，恕不另行通知。除非另有说明，多找找推广的所有目录和定制产品仅限于科研使用，不得用于人类或动物的诊断或治疗。